ZTS

ZTS

USD

Zoetis Inc. Class A Common Stock

$119.830-0.600 (-0.498%)

السعر في الوقت الحقيقي

Healthcare
Drug Manufacturers - Specialty & Generic
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$120.430

الأعلى

$121.310

الأدنى

$118.520

الحجم

8.35M

أساسيات الشركة

القيمة السوقية

52.8B

الصناعة

Drug Manufacturers - Specialty & Generic

البلد

United States

إحصاءات التداول

متوسط الحجم

3.12M

البورصة

NYQ

العملة

USD

نطاق 52 أسبوعاً

الأدنى $117.26الحالي $119.830الأعلى $181.85

أخبار ذات صلة

Analyst Upgrades

Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $175

Morgan Stanley analyst Erin Wright maintains Zoetis with a Overweight and lowers the price target from $211 to $175.

عرض المزيد
Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $175
Analyst Upgrades

Zoetis Stock Outlook Clouded By Rising Competitive Pressures

Zoetis tops Q3 earnings estimates but trims 2025 sales forecast as companion animal growth slows and competition weighs on its outlook.

عرض المزيد
Zoetis Stock Outlook Clouded By Rising Competitive Pressures
BusinessWire

Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career

عرض المزيد
Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026
BusinessWire

Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing

عرض المزيد
Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
BusinessWire

Zoetis Appoints Stephanie Tilenius to its Board of Directors

Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as

عرض المزيد
Zoetis Appoints Stephanie Tilenius to its Board of Directors

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.